Related Experiment Video
Updated: Apr 26, 2026
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Dual antiplatelet therapy after noncardioembolic ischemic stroke or transient ischemic attack: pros and cons
1Department of Neurology, Stroke Center, Ilsan Paik Hospital, Inje University, Goyang, Korea.
Insights
Dual antiplatelet therapy reduces recurrent stroke risk after TIA or ischemic stroke, but carries bleeding risks. Early therapy shows benefits, while long-term use requires careful risk-benefit assessment for patients.
Area of Science:
- Cardiology
- Neurology
- Vascular Medicine
Background:
- Dual antiplatelet therapy (DAPT) inhibits platelet activation via multiple pathways, potentially offering greater efficacy than monotherapy.
- Aspirin plus clopidogrel DAPT is standard for acute coronary syndrome and percutaneous coronary intervention but increases bleeding risk.
- Patients with ischemic stroke or transient ischemic attack (TIA) are often older with fragile cerebrovascular beds, heightening bleeding risks, including intracranial hemorrhage.
Purpose of the Study:
- To evaluate the efficacy and safety of dual antiplatelet therapy compared to monotherapy in patients with noncardioembolic ischemic stroke or TIA.
- To analyze the benefits of early DAPT initiation versus long-term therapy in this patient population.
Main Methods:
- Review of clinical trials and meta-analyses comparing dual antiplatelet therapy with antiplatelet monotherapy.
- Assessment of outcomes including recurrent stroke, major vascular events, and major bleeding events (including intracranial hemorrhage).
Main Results:
- Early DAPT initiation after noncardioembolic ischemic stroke or TIA reduces recurrent stroke and major vascular events without significantly increasing major bleeding.
- Long-term DAPT data in stroke/TIA patients show inconsistent benefits over monotherapy.
- Increased harm from major bleeding events, particularly intracranial hemorrhage, is a concern with long-term DAPT.
Conclusions:
- Early dual antiplatelet therapy is beneficial for noncardioembolic ischemic stroke and TIA patients.
- Long-term use of dual antiplatelet therapy in these patients requires careful consideration of increased bleeding risks, especially intracranial hemorrhage.
- Physicians must weigh the benefits against the risks of DAPT versus monotherapy for individual stroke/TIA patients.
Abstract:
Dual antiplatelet therapy simultaneously blocks different platelet activation pathways and might thus be more potent at inhibiting platelet activation and more effective at reducing major ischemic vascular events compared to antiplatelet monotherapy. Aspirin plus clopidogrel dual therapy is now the standard therapy for patients with acute coronary syndrome and for those undergoing percutaneous coronary intervention. However, dual antiplatelet therapy carries an increased risk of bleeding. Patients with ischemic stroke or transient ischemic attack (TIA) are generally older and likely to have a fragile cerebrovascular bed, which further increases the risk of systemic major bleeding events and intracranial hemorrhage. Clinical trials and meta-analyses suggest that in comparison to antiplatelet monotherapy, dual antiplatelet therapy initiated early after noncardioembolic ischemic stroke or TIA further reduces the rate of recurrent stroke and major vascular events without significantly increasing the rate of major bleeding events. In contrast, studies of long-term therapy in patients with noncardioembolic ischemic stroke or TIA have yielded inconsistent data regarding the benefit of dual antiplatelet therapy over monotherapy. However, the harm associated with major bleeding events, including intracranial hemorrhage, which is generally more disabling and more fatal than ischemic stroke, is likely to increase with dual antiplatelet therapy. Physicians should carefully assess the benefits and risks of dual antiplatelet therapy versus antiplatelet monotherapy when managing patients with ischemic stroke or TIA.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Transient Ischemic Attack l: Introduction
01:27Coronary Artery Disease V: Interprofessional Care
01:27Peripheral Artery Disease III: Interprofessional Care
01:29Venous Thrombosis III: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...